"Using spot prices markedly increases the valuation to over $12ps, again including only half the sulphides."So if you include 100% of the sulphides then the spot valuation should be $24 per share.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%